SCHEMBL4922690

SCHEMBL4922690

O=C(Nc1ccc(N2CCCCC2)c(F)c1)Nc1ccc2c(c1)OCCO2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.59
KMT2A Q03164 7/20 0.59
MAPT P10636 6/20 0.59
MEN1 O00255 6/20 0.59
ALDH1A1 P00352 4/20 0.59
LMNA P02545 4/20 0.59
HTT P42858 1/20 0.59
RAB9A P51151 12/20 0.58
NPC1 O15118 11/20 0.58
NFKB1 P19838 2/20 0.58
NFKB2 Q00653 2/20 0.58
RELA Q04206 2/20 0.58
POLB P06746 2/20 0.58
HPGD P15428 2/20 0.53
CYP2C9 P11712 1/20 0.53
ALOX12 P18054 1/20 0.53
CYP2C19 P33261 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
TP53 P04637 3/20 0.53
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4920583 0.93 RAB9A (0.62) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1
SCHEMBL4919385 0.87 MAPT (0.46) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1
SCHEMBL4923650 0.82 NPC1 (0.55) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1
SCHEMBL5176497 0.80 CNR1 (0.57) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1
SCHEMBL4922838 0.80 CNR1 (0.57) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1
SCHEMBL4920276 0.80 CNR1 (0.57) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1
SCHEMBL4920516 0.79 SLC2A1 (0.59) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1
SCHEMBL4924794 0.79 MAPT (0.50) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1
SCHEMBL4921571 0.79 MAPT (0.60) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1
SCHEMBL4919660 0.79 CNR1 (0.59) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP claimed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R SMN1; SMN2 3931/4885KMT2A 1905/4885MAPT 4151/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R SMN1; SMN2 3931/4885KMT2A 1905/4885MAPT 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.